In the Motley Fool comparison dated October 4, 2026, Novo Nordisk looks stronger than Pfizer on earnings-based dividend payout, while Pfizer looks stronger on the article’s cash-dividend payout comparison. That split is why neither a headline yield nor a single payout ratio is enough to judge dividend safety. The figures below are attributed to the article unless identified as company-reported annual results; they are not an independently verified investment recommendation.
What the traditional metrics say
Reuben Gregg Brewer’s Motley Fool article reports a 4.7% yield for Novo Nordisk and a 6% yield for Pfizer, alongside earnings payout ratios of 33% and 220%, respectively. On those conventional measures, Novo has the lower yield but much more room between earnings and dividends; Pfizer’s reported earnings payout ratio is above 100%.
As an Amazon Associate I earn from qualifying purchases.
The same article reports cash-dividend payout ratios of roughly 110% for Novo and about 90% for Pfizer. That reverses the apparent advantage: on the article’s cash measure, Pfizer’s dividend consumes a smaller share of the relevant cash flow. The source does not establish the exact dates, inputs, or calculation method for each ratio, so these should be treated as the article’s snapshot, not fresh calculations. Read the Motley Fool comparison.
Why the ratios can disagree
An earnings payout ratio compares dividends with an earnings measure; a cash-dividend payout ratio compares cash dividends with a cash-flow measure. Earnings and cash flow differ because of non-cash accounting items, working-capital changes, capital expenditure, and other cash demands. The denominator also matters: a ratio using operating cash flow will not mean the same thing as one using free cash flow after capital spending.
#1 Best Overall
For any ratio, the useful questions are what period it covers, which earnings or cash-flow definition it uses, whether dividends are on a per-share or total-cash basis, and whether the numerator and denominator use the same currency and reporting period. The article’s reported figures do not supply enough detail to reconcile its exact cash-ratio calculations.
What the companies’ 2025 figures add
Company-reported annual results provide dated context, but they are not necessarily the inputs behind the Motley Fool article’s payout ratios.
Rank #2
| Company | 2025 reported figure | What it establishes |
|---|---|---|
| Novo Nordisk | Total dividend of DKK 11.70 per share; 50.7% dividend payout ratio | The company’s annual report gives these annual dividend measures. Its payout ratio is the company’s reported measure, not automatically a cash-flow payout ratio. Novo Nordisk 2025 Annual Report |
| Novo Nordisk | DKK 28.3 billion free cash flow | The annual report reports this free cash flow. The report notes a substantial prior-year acquisition effect, so a year-to-year comparison needs that context. Novo Nordisk 2025 Annual Report |
| Pfizer | $62.579 billion revenue; $11.704 billion net cash provided by operating activities; $9.771 billion cash dividends paid | These are Pfizer’s company-reported 2025 figures. They show the scale of the annual cash dividend relative to operating cash generation, but do not by themselves reproduce the Motley Fool article’s roughly 90% calculation. Pfizer 2025 Annual Report |
Novo’s 2025 dividend and payout figures are also confirmed in its March 26, 2026 AGM announcement. The announcement’s company leadership commentary describes a period of transformation; that strategic characterization is not evidence of dividend safety.
Recommended Free Tools
Yield is income, not a safety score
The 6% Pfizer yield and 4.7% Novo Nordisk yield are figures reported by the article dated October 4, 2026. Yield changes when a share price moves and when a company declares or changes its dividend. The article does not make those percentages permanent rates, and they should not be carried forward as current yields without checking contemporaneous prices and declared dividends.
A higher yield can reflect a larger dividend, a lower share price, or both. It does not show whether future earnings and cash flow will support the payment. Likewise, a lower yield does not by itself mean a dividend is safer.
Business risks differ
Brewer’s article characterizes Novo Nordisk as more concentrated in its core drug categories and describes the company as shifting toward volume. It portrays Pfizer as having a broader portfolio while facing patent expirations and the challenge of replacing revenue through its pipeline. These are the article author’s qualitative assessments, not a current independent review of product competition, clinical results, regulatory decisions, or patent timelines.
Rank #4
Those risk profiles matter to dividends because a payout depends on future cash generation, not just one year’s accounting ratio. A concentrated business may be more exposed to changes in its major categories; a broader portfolio can still face revenue gaps if key products lose exclusivity or replacement products underperform. The available comparison does not quantify how likely or large those outcomes are.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteHow to interpret the comparison
- If you focus on earnings payout: the article’s reported 33% for Novo versus 220% for Pfizer favors Novo on that metric.
- If you focus on the article’s cash payout comparison: its reported roughly 110% for Novo versus about 90% for Pfizer favors Pfizer, though the underlying formula and period are not established.
- If you focus on yield: the article reports Pfizer higher on October 4, 2026, but yield alone does not establish sustainability.
- If you focus on company-reported annual context: Novo disclosed a 50.7% 2025 dividend payout ratio and DKK 28.3 billion free cash flow; Pfizer reported $11.704 billion operating cash flow and $9.771 billion dividends paid in 2025. These measures have different definitions and should not be treated as directly interchangeable.
The article’s cautious conclusion is that both companies carry material dividend risks and that Pfizer’s higher reported yield may be more attractive after weighing those risks. That is the author’s interpretation, not a conclusion established by the payout figures alone. A reader comparing the stocks should verify the current dividend, share price, latest cash flow, business outlook, and the exact definitions behind any payout ratio before relying on a yield snapshot.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
